Floatz Rating
CC42/100
Confidence
Indicative
Sponsor
SOLTI Breast Cancer Research Group
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
35High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04802876CT.gov Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors | — | Active Not Recruiting | — | — | — |
NCT04294160CT.gov A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer | — | Terminated | — | — | — |
NCT04000529CT.gov Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies | — | Terminated | — | — | — |
NCT03891953CT.gov Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. | — | Active Not Recruiting | — | — | — |
NCT03668431CT.gov Dabrafenib + Trametinib + PDR001 In Colorectal Cancer | — | Unknown | — | — | — |
NCT03549000CT.gov A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. | — | Terminated | — | — | — |
NCT03176264CT.gov PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer | — | Terminated | — | — | — |
NCT03207867CT.gov A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma | — | Terminated | — | — | — |
NCT03081494CT.gov Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT02947165CT.gov Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. | — | Completed | — | — | — |
Show 1 more trialShow fewer
NCT01351103CT.gov A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Spartalizumab (this asset) | SOLTI Breast Cancer Research Group | P2 | CC · 42 |
| Fluorouracilum | UNICANCER | P4 | BB |
| Oxaliplatin | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | P4 | BB |
| Irinotecan | UNICANCER | P4 | BB |
| Levofolinic Acid | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BB |
| Moviprep | Radboud University Medical Center | P4 | BB |
| Capecitabine | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | P4 | BB |
| Regorafenib | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | P4 | BB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BB |
+42 more in the Colorectal Cancer cohort
Other indications for Spartalizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Pancreatic Adenocarcinoma | — | P3 | CCC · 54 |
| Melanoma | — | P3 | CCC · 52 |
| Triple-Negative Breast Carcinoma | — | P2 | CCC · 52 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Spartalizumab in Colorectal Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/spartalizumab-colorectal-cancer-56934
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →